As promised, our agenda is finally announced!!

Let’s keep this momentum going!!!

NEWS: NIH launches $21 million initiative to improve understanding of sex-specific hormonal biology. Read the full story ➡️ bit.ly/4h56xWy.

Good writing and any improvement in this area will go a long way for patients! BUT its central diagnosis (that the science is largely ready and development is now the bottleneck) fits oncology far better than neurodegeneration.🧠 We have not solved the upstream science in Alzheimer's or Parkinson's. We have few (I'd argue, no) therapies for their root causes. These diseases unfold for years or decades before before they become clinically detectable, often through very noisy readouts. So even if you had a potential treatment at hand, it could take a long, looong time before you'd be able to detect an improvement. Faster Ph1 trials are not the (primary) solution for fixing this fundamentally broken feedback loop. Instead, we'd need better experimental systems, biomarkers and longitudinal data that lets us learn much faster from the bench to patients. Case in point:

For years, critics have labeled Capitol Hill a "gerontocracy." The AP News Congressional Retirements Tracker shows a massive wave of lawmakers heading for the exits this election cycle, while underscoring a broader trend: Congress has steadily aged over the last century. While dozens of members are not seeking reelection to their current seats, many aren't stepping away from public life entirely, opting instead to pursue governorships or Senate seats. As a new generation of leaders steps up, we’ll be watching to see how the demographic landscape of Congress evolves. Nonetheless, the timing and opportunity for aging biology and longevity biotechnology have never been more ripe. At A4LI, we continue to champion this vision by advocating for policies that accelerate next-generation disease-modifying therapies. By pairing longer lifespans with vibrant healthspans, we ensure everyone has the energy to pursue what they love and the opportunity to pivot careers at any stage of life. Source: apnews.com/projects/2026-con…

Had a great time chatting with Christina about her journey in science and her current work looking at senescence in the gut in non-human primates at @WakeForest!

Thank you for the invitation, @agingdoc1! @theA4LI

What role should public policy play in extending healthy human lifespan? Our Founder, @dullunlivin, recently joined the @LongevityTech UNLOCKED podcast to discuss why advancing longevity science requires more than scientific breakthroughs. It also requires policies that help bring those breakthroughs to the people who need them. The conversation explores the growing momentum behind longevity policy, the challenges that remain, and why now is the time to rethink how governments approach healthy aging. 🎥 You can watch the full interview here: piped.video/watch?v=LCl0oQ5k…

🧠 Longevity Fact of the Week 12.4 years. That's the average gap between lifespan and healthspan in the United States. In other words, the average American spends more than 12 years living with disease or disability before the end of life. While we have made remarkable progress in helping people live longer, the next challenge is helping people stay healthier for longer. At A4LI, we have made it our mission to advance policies that accelerate the development of therapies targeting the biology of aging, with the goal of extending not just lifespan, but healthspan as well. 📖 Learn more about the research behind the healthspan gap here: pmc.ncbi.nlm.nih.gov/article…

A great recap if you couldn’t join us last week! Thanks for the opportunity @LongevityTech!

Last week, we hosted our biggest and most impactful D.C. Summit yet. Across three days, we welcomed 250+ attendees, brought together 60+ leaders across the biotech and policymaking space, and facilitated 40+ meetings between longevity stakeholders and Members of Congress. That is why NOW is the time we capitalize on this momentum. Here’s how you can help: 1️⃣ Back Our Petitions Pledge your support for our White Papers on Action Network (actionnetwork.org/groups/the…) to help key decision makers understand the importance of longevity science. 2️⃣ Share with your Network Every signature helps. Help us raise awareness for these initiatives. Thank you to everyone who attended this year’s Summit, as well as all of you who have supported us over the years. None of this would be possible without you. Together, we can create a world in which everyone can live healthier, longer lives.

Last chance and we mean it!!!!

Our H-SPAN Summit DC is just around the corner. This year, we’re building on last year’s conversation about cross-agency alignment in funding and regulatory frameworks for longevity. We are thrilled to close Day 2 of the Summit with a landmark session: “Building the Framework: Policy Levers for Longevity Innovation.” For the first time, senior administration leaders and Members of Congress will join in a singular forum to discuss current federal initiatives and legislative levers that set out to make healthy longevity a national priority and achieve a true "longevity dividend." Featured speakers for this policy-focused second day include: •Dr. Mehmet Oz (Tentative), Administrator of the Centers for Medicare & Medicaid Services (CMS) •Lowell M. Zeta, Acting Chief of Staff and Deputy Commissioner for Strategic Initiatives, U.S. Food and Drug Administration (FDA) •Dr. Alicia Jackson, Director of the Advanced Research Projects Agency for Health (ARPA-H) •Congressman Kevin Mullin (CA-14), Representative of the Bay Area Longevity Biotech Ecosystem •Congressman Jim McGovern (MA-2), Ranking Member of the House Rules Committee and Champion for Nutrition and Healthy Aging Policy •Congressman Paul Tonko (NY-20), Co-chair of the Congressional Longevity Science Caucus

Russia has committed $26 billion to longevity science, while China is advancing large-scale stem cell anti-aging trials and expanding aggressive investment in regenerative medicine and longevity biotechnology. Scientific leadership in longevity is rapidly becoming a defining frontier of global competitiveness. The United States cannot afford to sit on the sidelines. Join our letter campaign: actionnetwork.org/letters/th…

A positive signal that the longevity ecosystem is gaining the critical visibility it needs from state lawmakers. Excited to get started!

HB 1735 has passed the New Hampshire Senate. The bill was amended during the legislative process, but its passage reflects growing recognition that patients and innovators deserve greater flexibility when pursuing promising longevity therapies. "The final bill is more limited than we originally hoped for, but it's encouraging to see states like New Hampshire continue engaging with these issues,” said Dylan V. Livingston, Founder and CEO of @theA4LI. “The reality is that patients are looking for more options, and policymakers across the country are increasingly willing to have that conversation." We are grateful to the many New Hampshire leaders who championed HB 1735, including Governor @KellyAyotte and @NHSpeaker Sherman Packard. We also extend our thanks to the stakeholders, advocates, and volunteers who dedicated their time and energy to supporting the legislation and advancing the conversation around patient access and medical innovation.

This resolution is a positive signal that the longevity ecosystem in CA is gaining critical visibility it needs!

If you’re interested in attending, please reach out. This is the year to be in DC, and your presence and voice are incredibly important!

Thank you for highlighting the momentum we have been building since our inaugural event in 2024, @LongevityTech! Incredible to see how far the conversation has moved from speculative science to serious national policy in just three years. Read it here: longevity.technology/news/h-… @bioagelabs @RetroBio_ @KarlPfleger @soniaarrison @mkaeberlein @DrMikeRoizen @BuckInstitute @aubreydegrey

This is the most ambitious agenda we’ve put together so far!

I’m thrilled to announce my new podcast, Longevity Science with Matt Kaeberlein. Episode 1 is now live and takes a deep dive into the story of dinitrophenol (DNP) — an experimental weight loss drug linked to hundreds of deaths and a cautionary reminder of what can happen when enthusiasm for new therapies gets ahead of the science. Episode 2 drops Friday and features a Longevity Roundtable with @BKennedy_aging and @docmranney . We discuss proactive healthcare, rapamycin, peptides, epigenetic reprogramming, biological age testing, and where the field of longevity medicine may be headed next. My goal with this channel is simple: thoughtful, evidence-based conversations that separate signal from noise in the rapidly evolving world of longevity science. I hope you’ll check it out — and subscribe on YouTube, Spotify, or wherever you listen to podcasts. YouTube: piped.video/@mkaeberlein Spotify: open.spotify.com/show/7DRRH5…